Clinical Trial Update: A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/Phase 2 study evaluating AT13387 in non-small cell lung cancer, both as monotherapy and in combination with crizotinib. The trial status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AT13387 (AT13387)
• Crizotinib (crizotinib)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Non-small Cell Lung Cancer(NSCLC) | Phase 1, Phase 2 | Status: COMPLETED